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Abstract 
There are over 15,000 known variants that cause human inherited disease by disrupting splicing [GILL: 
According to the latest version HGMD, we have logged ~19,800 splicing-relevant lesions out of a total of 
~220,000 mutations (9%)]. While there are a few in silico methods, such as CADD, EIGEN and LINSIGHT, 
that predict the pathogenicity of noncoding variants, none are focused explicitly [GILL: Do you mean 
exclusively?] on splicing and none are able to effectively distinguish pathogenic splicing variants from 
benign variants. We introduce S-CAP, a novel splicing pathogenicity predictor that reduces the number 
of splicing variants of uncertain significance in patient exomes by 41%, a nearly 3-fold improvement over 
existing noncoding pathogenicity measures, while correctly classifying known pathogenic splicing 
variants with a clinical-grade 95% sensitivity. 
Introduction 
 Genomic sequencing, and in particular exome sequencing, is revolutionizing the diagnosis of 
Mendelian disease, with over 5,000 genetic diseases already successfully mapped to over 3,000 genes 
[GILL: I think you will find that this is an underestimate, both in terms of the number of genetic diseases 
and the number of disease genes]. The sifting of patient exomes in search of a causal variant is a time-
consuming process that often focuses on the coding sequence (CDS) of genes1–4. Powerful pathogenicity 
meta-predictors such as M-CAP5 integrate multiple primary predictors such as SIFT6 and Polyphen-27 
with cross-species sequence conservation features to offer accurate clinical grade predictions capable of 
missing only a tiny fraction [GILL: a small proportion?] of known coding pathogenic mutations. This 
efficiency is important [GILL: you could say that both sensitivity and specificity are important?], because 
reducing the size of the candidate list of variants of uncertain significance (VUS) is futile if the 
pathogenic variant itself is incorrectly classified as benign8.  
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               M-CAP is commonly used by clinicians to prioritize nonsynonymous variants9,10, so that they can 
effectively consider first the variants that are most likely to yield a diagnosis. However, with diagnostic 
rates at 30-50%, one must look beyond the CDS itself. Splicing is a complex and crucial step of gene 
expression, wherein vast sections of RNA, called introns, are removed from a pre-messenger RNA and 
the remaining RNA, called exons, are joined together to form the mature messenger RNA (mRNA). 
Changes in splicing induced by genetic variants can have severe impacts on the protein coding potential 
of an mRNA, such as the exclusion of an entire exon11 or a frameshift12,13 induced by creation of a new 
splice site14, among other effects15–17. Exome sequencing captures sequence information up to 50 base 
pairs past exon boundaries into each adjacent intron18.  This region covers a broad class of splice 
affecting [GILL: splicing-relevant? splice-disrupting?] variants: those that disrupt existing splice sites or 
exonic and proximal intronic splicing regulators, such as the branchpoint, and some that create new 
splice sites.  
Indeed, there are nearly 20,000 known Mendelian disease causing variants that impact the gene 
product through RNA splicing19,20. However, a typical singleton patient͛s exome contains over 500 
variants of uncertain significance (VUS)21 and (as we show) there currently exist no tools adequate for 
the purpose of interpreting these variants. Pathogenicity prediction tools such as CADD22, EIGEN23 and 
LINSIGHT24 have attempted to tackle a broad spectrum of non-coding mutations, but in doing so they 
neither focus on predicting splicing variant pathogenicity, nor do they provide any clinical grade 
assurances of minimizing the false prediction of known pathogenic splicing variants as benign. Generic 
methods also ignore the rich literature characterizing mRNA splicing and predicting associated molecular 
phenotypes, such as the percentage-spliced-in of exons25–28. These findings and methods provide 
invaluable insight into the potential of a variant to disrupt splicing. However, the splicing literature does 
not tell the whole story either, as predicting molecular phenotypes is a fundamentally different task 
from predicting if a variant will cause a disease. For a variant to cause a disease, the variant must disrupt 
normal splicing in one or more relevant tissues and the induced change in mRNA phenotype must be 
pathogenic. Similar obstacles are met in the few cases where clinicians attempt to identify patient 
genetic variants that disrupt splicing by performing a costly and time consuming RNA-seq experiment in 
an accessible, but not necessarily disease relevant, cell population29,30. 
We introduce S-CAP (Splicing Clinically Applicable Pathogenicity), a machine learning tool that 
integrates knowledge of splicing with measures of variant, exon and gene importance into a splicing-
specific pathogenicity score. We evaluate S-CAP at the high sensitivity required in clinical settings and 
show that it far outperforms existing non-coding pathogenicity scores, as well as tools focused solely on 
identifying synonymous variants that disrupt splicing. S-CAP will allow clinicians to consider a broad class 
of splice-impacting variants, resulting in the diagnosis of more patients suffering from Mendelian 
disease. 
Results 
We developed a machine-learning framework to model and evaluate splicing variant pathogenicity. We 
analyzed the positional distribution and potential functional effects of variants near splice sites and 
defined 6 regions that displayed distinct mutation rates and functional effects. We trained 6 models (1 
per region) to predict splicing variant pathogenicity. This involved building (i) a labeled dataset of known 
pathogenic and benign splicing variants, (ii) a set of features to help discriminate between the 
pathogenic and benign variants in each region and (iii) a learning algorithm to identify patterns in the 
features and to distinguish between variants in the two classes. Finally, we evaluated our models on a 
[[GILL: presumably unrelated] set of known pathogenic and benign variants, as well as over a dozen 
individuals with diseases caused by splice affecting [GILL: splicing-relevant? splice-disrupting?] variants. 
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The landscape of splice region variation 
To build a dataset of labeled splicing variants, we considered variant pathogenicity, semantic effect and 
population frequency. We start by taking the union of 109,279 pathogenic single nucleotide variants 
(SNVs) from the Human Gene Mutation Database (HGMD) and 25,793 pathogenic SNVs from ClinVar to 
obtain a total of 114,382 unique pathogenic variants [GILL: you gained ~5,000 extra variants (4%) by 
including data from ClinVar. Personally, I am a little doubtful that this exercise was worth it. I may be 
somewhat biased but I do wonder if the additional ClinVar data are going to be as reliable as the 
mutation data from HGMD which have (i) all been peer-reviewed prior to publication and (ii) been 
independently assessed by our expert curators prior to inclusion in HGMD. I would not be surprised if 
your AUC values improved slightly if you confined your analysis to HGMD data. Maybe you should try 
this? No harŵ doŶe if I aŵ ǁroŶg….aŶd if I aŵ right, Ǉour results ǁill ďe eǀeŶ ŵore iŵpressiǀe]. We 
curated 15,833,389 benign SNVs observed in controls from the gnomAD database who do not suffer 
from any obvious Mendelian disease. To identify a subset of variants with likely impact on splicing, these 
sets were filtered to the ͚splicing region͛, i.e. all synonymous or intronic variants within 50 base-pairs18,31 
of an exon boundary (we justify the choice of name [GILL: term? splicing region?] below). Removing 
nonsynonymous and loss of function (stop gain or stop loss) variants ensured that our model was 
trained and evaluated virtually exclusively on splicing variants. The gnomAD variants were further 
filtered to remove any variant identified as being pathogenic in HGMD or ClinVar. This resulted in 14,938 
splicing pathogenic variants and 7,027,609 splicing benign variants. Then a frequency filter, based on the 
ACMG guidelines that suggest clinicians consider common (> 1% frequency) variants as definitively 
benign, was applied to both sets yielding 14,838 rare splicing pathogenic variants and 6,760,450 rare 
splicing benign variants. In support of this ACMG guideline, we note that only 100 of 14,938 (0.67%) 
known pathogenic variants in the splicing region are common in the general population (see Methods).  
To show that nearly all pathogenic ͚splicing region͛ variants do in fact disrupt splicing, we 
developed a simple model to assign a putative effect of variants on splicing. Among other factors, splice 
affecting [GILL: splicing-relevant? splice-disrupting?] mutations can (1) create a cryptic splice site (2) 
disrupt an existing splice site or (3) disrupt an existing branchpoint. We used the existing tools 
MaxEntScan and LaBranchoR, which predict the strength of splice site sequences and branchpoint 
sequences, respectively. We denoted a variant as creating a cryptic splice site if the variant creates a 
splice site with a MaxEntScan score at least as high as the score for the reference splice site (with the 
variant included), disrupting a splice site if it reduces the MaxEntScan32 score of the reference splice site 
by more than 1, and as disrupting a branchpoint if it has a LaBranchoR33 in silico mutagenesis score of 
less than -0.1. In cases where a variant had multiple putative effects, e.g. creating a cryptic splice site 
and disrupting an existing splice site, we resolved to the most extreme effect, which we took to be the 
order in which they are introduced above [GILL: I am unclear as to your meaning and even more unclear 
iŶ relatioŶ to hoǁ Ǉou estaďlish the order iŶ ǁhiĐh ͚theǇ are iŶtroduĐed͛. Do Ǉou ŵeaŶ the order iŶ 
which they are likely to impact the RNA splicing phenotype?]. We found that 97% of putatively 
pathogenic splicing variants are predicted to have an effect on splicing, as opposed to only 18% of likely 
benign variants (Fig. 1a-b). We also found that pathogenic variants are enriched at positions where the 
mechanistically essential U2 snRNA, U2AF, and U1 snRNA bind. Further, the positional distribution of 
pathogenic variants traces the bias in nucleotide content inside of these binding sites [GILL: meaning 
unclear!](Fig. 1b). Conversely, variants occurring in the general population are biased away from these 
high information content positions34 (Fig. 1a). 
Region-specific models to increase performance and alleviate ascertainment bias 
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In order to effectively capture these position-specific patterns, we separated the variants into 6 
regions relative to the splice sites with generally homogenous function and built a separate model for 
each region (Supplementary Fig. 1). Specifically, we grouped variants occurring in the oďligate ϱ͛ GT ;ϱ͛ 
core) aŶd ϯ͛ AG ;ϯ͛ ĐoreͿ dinucleotides, iŶtroŶiĐ ǀariaŶts upstreaŵ of a ϯ͛ss ;ϯ͛ iŶtroŶiĐͿ, variants lying in 
the canonical U1 snRNA binding site excluding the core ϱ͛ss (ϱ͛ extended), intronic variants downstream 
of a ϱ͛ss ;ϱ͛ iŶtroŶiĐͿ, and synonymous variants within the protein coding gene (exonic) (Fig. 1c). 
Core splice site variants are well known as having a large functional effect and are easy to 
identify, a fact that has probably led to an overrepresentation of core splice site variants in pathogenic 
variant databases. Around 73% of known splicing region pathogenic variants occur within the core splice 
sites (Fig. 1c). Although this is consistent with the mechanistic importance of these positions, in 
unbiased studies of splicing quantitative trait loci it is generally found that fewer than 1% of splicing 
affecting [GILL: splicing-relevant? splice-disrupting?] variants are found to be located in core splice 
sites35,36 and in a recent study employing RNA-seq data to identify splice-affecting [GILL: splicing-
relevant? splice-disrupting?] variants resulting in Mendelian disease, only 2 of 6 (33%) causal variants in 
the splicing region were in core splice sites29. If left unaddressed, this bias would allow a classifier to 
have strong test set performance (by calling most core splice site variants pathogenic and others 
benign), but would often miss non-core splice site pathogenic variants. Separating variants by position 
allows us to guarantee that pathogenic variants are rarely misclassified as benign in every region, 
thereby ensuring an overall low false negative rate irrespective of ascertainment biases present in 
annotated data. 
S-CAP features 
We curated existing metrics and developed several novel features to help distinguish between 
pathogenic and benign variants within the splicing region (Supplementary Table 1). The set consists of 
chromosome, gene, exon and variant level features. At the chromosome level, we add 3 features to 
distinguish between variants found on chromosome X, chromosome Y and the autosomes. Variants on 
the X chromosome present an important subcase [GILL: subset?] since in males, a hemizygous X 
chromosome variant inducing loss of function results in no viable gene product. Consistent with this 
intuition, pathogenic variants are highly enriched on the X chromosome as compared to the autosomes 
(7.11 fold enrichment, p < 10-140 by two-sided Fisher͛s Exact Test). At the gene level, pLI34, RVIS37, and a 
haploinsufficiency score38 help to measure the potential pathogenicity of each gene [GILL: meaning 
unclear. Are you referring to the Human Gene Damage Index? Do you mean the likelihood that a given 
gene is a ͚disease geŶe͛?]. At the exon level, exon length, exon length modulo 3, reference splice site 
strengths, an existing regional constraint score39 and the exon sequence similarity between hg19 and 99 
species from the 100way alignment serve to assist in distinguishing critical exons from those that may 
be safely excluded [GILL: Have I understood this correctly?]. Additionally, we developed a novel splice 
site constraint score to measure the fragility and tolerance of each exon to splice site mutations (see 
Online Methods). At the base-pair level, CADD22 measures pathogenicity based on functional data 
annotations, LINSIGHT measures variants͛ fitness effect through functional data and molecular 
evolution, whereas SPIDEX27 was incorporated in order to measure the impact of a given variant on exon 
inclusion. PhyloP40 and PhastCons41 scores from the multiz46way and multiz100way alignments measure 
the evolutionary importance of the affected base across primate species, placental mammals and all 
vertebrates. We also include a feature to capture the change in 3-mer content induced by a variant42.  
Additionally, we include region-specific features, such as a branchpoint disruption term for the ϯ͛ 
intronic region33 aŶd a ϱ͛ ĐrǇptiĐ spliĐe site creation term for the ϱ͛ iŶtroŶiĐ regioŶ (see Online Methods 
for a complete description of features). 
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The machine learning algorithm 
Similar to the M-CAP classifier5, S-CAP is built using a gradient boosting tree classifier, a highly effective 
machine learning model43. This model iteratively builds decision trees, where each tree is picked to 
correct the most cases that were misclassified in the previous step. The final classifier is a linear 
combination of each of the previously derived decision trees (see Online Methods for details). 
S-CAP consistently outperforms existing pathogenicity scores 
Each of the 6 previously described regions contains a set of pathogenic and benign variants (Fig. 1c), 
which were used to train 6 separate models. We performed 5-fold cross-validation and selected the 
median performing model as the final model for each region. S-CAP was evaluated against the most 
popular existing methods that score splice affecting [GILL: splicing-relevant? splice-disrupting?] variants: 
CADD, SPIDEX, LINSIGHT and EIGEN. Existing methods all performed at random or better (AUC of 0.46 - 
0.81) across the 6 defined splicing regions (Fig. 2a-f).  The 6 S-CAP models outperformed all existing 
methods in all regions resulting in up to a 26.6% improvement in the AUC over the next best performing 
model. S-CAP performance ranged from achieving an AUC of 0.804 in the 3͛ Đore regioŶ ;Fig. 2b) to 
achieving an AUC of 0.953 iŶ the ϯ͛ iŶtroŶiĐ regioŶ ;Fig. 2a). No existing method consistently 
outperforms other existing metrics across all splicing regions (Fig. 2a-f). 
Additionally, S-CAP performance on exonic variants was independently compared against 
MutPred Splice (see Supplementary Figure 2)42, a tool focused on scoring only splice affecting [GILL: 
splicing-relevant? splice-disrupting?] synonymous variants. As MutPred Splice was trained using the 
same data used to build S-CAP, a random train and test split of data may have resulted in the inclusion 
of variants in the test set that were used to train the MutPred Splice classifier. To ensure zero 
information leakage between the training and test datasets, we carefully built a test set that excluded all 
MutPred Splice training data.  
Clinically relevant threshold maintains high sensitivity 
As previously shown in M-CAP5, it is important to tune thresholds for clinical settings so that fewer than 
5% of known pathogenic variants are misclassified. None of LINSIGHT, EIGEN or SPIDEX provides a 
default threshold to consider a variant as pathogenic. As a result, it is difficult to use any of these 
methods for variant pathogenicity classification. CADD provides a threshold but, at the author-
recommended default threshold, over 31% of the known pathogenic variants across the splice region 
are discarded and incorrectly classified as benign (Table 1). Similarly, MutPred Splice provides a default 
threshold, but over 48% of known pathogenic exonic variants are misclassified at this threshold. We 
generated a high sensitivity threshold for all metrics in each region by finding the lowest threshold that 
results in the correct classification of at least 95% of a test set of pathogenic variants from that region 
(Table 2). 
S-CAP excels at clinically relevant thresholds 
Moving into the high sensitivity domain, S-CAP͛s perforŵaŶĐe (Supplementary Fig. 3a-f) ranged from 
achieving an hsr-AUC of 0.186 in the exonic region (Supplementary Fig. 3c) to an hsr-AUC of 0.549 hsr-
AUC iŶ the ϯ͛ iŶtroŶiĐ regioŶ (Supplementary Fig. 3a). When evaluating MutPred Splice on an 
independent test set of exonic variants, S-CAP achieves an hsr-AUC of 0.204 and outperforms MutPred 
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Splice which achieves an hsr-AUC of 0.081. Overall, S-CAP improves on existing metrics by up to 472% 
when focused on the high sensitivity domain.  
Different patterns observed for recessive and dominant variants 
Recessive and dominant diseases are associated with different selective pressure on alleles, which we 
hypothesized would result in different feature importances and thresholds for determining variant 
pathogenicity. To address this complexity, we developed separate classifiers for dominant (heterozygous 
in patient) and recessive (homozygous in patient) alleles. In patients, we are given whether each variant 
appears in the heterozygous or homozygous state. However, our training data did not provide dominant 
and recessive labels, so we developed a framework for inferring this information from a control 
population for model training (see Methods). 
Tagging 3͛ aŶd ϱ͛ core variants as dominant or recessive resulted in improved performance 
Supplementary Fig. 4a-h) compared to models without these tags (Fig. 2b,d). For ϯ͛ Đore ǀariaŶts, we 
built a model that improved upon an AUC of 0.804 and hsr-AUC of 0.257 froŵ the origiŶal ϯ͛ Core ŵodel 
to an AUC of 0.805 and 0.890 (Supplementary Fig. 4c,d) and hsr-AUC of 0.296 and 0.454 
(Supplementary Fig. 4g,h) when tested on just dominant or recessive variants, respectively. Similarly, 
for ϱ͛ core variants, we built a model that improved upon an AUC of 0.805 and hsr-AUC of 0.291 from 
the origiŶal ϱ͛ core model to achieve an AUC of 0.779 and 0.880 (Supplementary Fig. 4a,b) and hsr-AUC 
of 0.222 and 0.518 (Supplementary Fig. 4e,f) when testing on just dominant or recessive variants, 
respectively. The S-CAP model to be used on patients takes advantage of these split dominant and 
recessive models. 
S-CAP eliminates the most VUS in patient exomes 
Resources like S-CAP are developed on large sets of benign and pathogenic variants but ultimately are 
used to help with the interpretation of VUS in individual patients (Fig. 1C). To demonstrate the practical 
utility of S-CAP, we evaluated S-CAP and each of the comparison methods on 14 patients with 
Mendelian diseases caused by splice-altering mutations. After applying the standard allele frequency 
filter of ч 1%, a typical individual has on average a total of 533 rare variants within the splicing region 
(Fig. 1C). TǇpiĐallǇ, ~ϯϮ% of ǀariaŶts ǁere oďserǀed iŶ eaĐh of the ϱ͛ iŶtroŶiĐ, eǆoŶiĐ aŶd ϯ͛ iŶtroŶiĐ 
regions. 3% were iŶ the ϱ͛ extended regions and 0-3 variants were iŶ eaĐh of the ϯ͛ Đore aŶd ϱ͛ Đore 
regions (Fig. 1c). Existing methods, CADD, LINSIGHT, EIGEN and SPIDEX, using the 95% sensitivity 
thresholds (Table 2), perform comparably when applied to all VUS in the splicing region of an individual 
patient and on average reduce the number of VUS by up to 15%. By contrast, S-CAP is much more 
powerful, reducing the number of VUS in the splicing region for an individual patient by 31-46% (Fig. 3c), 
while confidently retaining the pathogenic variant for further detailed analysis (Table 3). For a larger 
sample size, we evaluated each method on all (n=2054) individuals in the 1000 Genomes Project21, 
which can conceptually be thought of as Mendelian disease patients with their pathogenic variants 
removed (see Fig. 1C). The observed fraction of VUS reduced on average per 1000GP individual is 
consistent with the performance observed when applied to patients (Fig. 3d). Specifically, S-CAP is 
nearly three times as powerful as existing methods and on average results in a 41% reduction of the VUS 
within the splicing region of a given individual. 
Discussion 
 7 
Variants affecting splicing comprise the second largest category of known pathogenic mutations20. A 
broad class of potential splice affecting [GILL: splicing-relevant? splice-disrupting?] variants are already 
being captured by exome sequencing, yet clinicians often ignore these variants because they do not 
have the proper tools to interpret them. Here we address this problem by developing S-CAP, the first 
clinically applicable pathogenicity predictor dedicated exclusively to splicing variants. 
In order for an in silico pathogenicity predictor to be useful in the clinic, it needs to be easy to 
use, carefully evaluated at high sensitivity and confidently removes a substantial fraction of benign 
variants. Existing noncoding variant tools are not easy to use for splicing variants because their 
performance is strongly dependent upon position relative to splice sites, classification thresholds are 
either not provided or poorly calibrated, and no single method consistently outperforms the others. This 
means that employing existing methods, a clinician would have to consult multiple pathogenicity scores 
for variants in different regions. Furthermore, none of the existing methods have been carefully 
evaluated at clinical-grade sensitivity and most methods give no guidance about what cutoff should be 
used. Of the methods that do suggest a cutoff, all result in the misclassification of an unacceptably high 
number of pathogenic variants (Table 1). After carefully evaluating the existing methods, we found that 
none of them confidently removed a considerable fraction of benign variants (Figure 3). For example, 
after we retuned it (Table 2), SPIDEX performed well on variants in the intronic bins, but was close to 
random at predicting the pathogenicity of core splice site variants. After retuning, CADD (Table 1,2) 
performed well on core and exonic variants but poorly on intronic variants (Figure 2). S-CAP, addresses 
these important issues, as it consistently outperforms existing methods across all the regions, its 
performance has been carefully evaluated at clinical-grade sensitivity, and it removes close to three 
times as many benign variants as any other existing method (Figure 3).  
Central to the design of S-CAP is the use of region-specific models to alleviate the effects of 
ascertainment biases in curated pathogenic variant databases. Curated pathogenic variant databases 
contain invaluable information about the properties of pathogenic variants, but they also over-represent 
variants in known disease genes and [GILL: in association with?] easily identifiable features. Of particular 
concern in splicing pathogenicity prediction is the inflated number of variants in core splice sites, which 
exists because they are easily recognized and have well established molecular consequences. If left 
unaddressed, this bias in the labeled pathogenic data would lead to unrealistic model performance, as a 
model could achieve relatively high test set performance simply by predicting that all core splice site 
variants are pathogenic and all others are benign. However, in the clinic, such a model would incorrectly 
classify pathogenic, non-core splice site variants as benign at an unacceptably high rate. Introducing 
separate models for each region alleviates this concern since each model͛s performance is evaluated 
using data from the same region, thereby assuring high sensitivity irrespective of the underlying 
positional distribution of pathogenic variants. Additionally, we allowed for the over-representation of 
pathogenic variants in known disease-associated genes by ensuring that variants from the same gene 
were never split between the training and evaluation sets (see Methods). This guaranteed that no gene 
level information was shared by features across folds. 
The use of patient RNA-sequencing (RNA-seq) data to identify pathogenic variants that disrupt 
splicing is a growing and promising field29,30,44 to which we believe S-CAP is complementary. In fact, our 
model already includes scores from SPIDEX27, a deep learning model that was trained on tissue-specific 
RNA-seq data to predict the change in percent spliced-in (��) of an exon given a variant. It would only 
be a small step to supplementing these predicted ��s with experimentally measured ��s from RNA-
seq experiments. Observing �� through RNA-seq bypasses the difficult problem of explicitly or implicitly 
predicting the effect of a given variant on splicing in a particular cell type, but this is only part of the 
problem. Whether predicted or measured, gene expression and � values vary between cell contexts and 
time points and in many cases the most relevant cell population to sequence would not be clear30,45. 
Perhaps even more importantly, molecular phenotypes are multiple steps away from real phenotypic 
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change, making it difficult to predict organismal pathogenicity from molecular phenotype46. These 
factors limit the direct applicability of observed or predicted ��s to cases where there is a good 
understanding of the relationship between a disease, the cell population it affects, and the set of 
potentially causative genes. Many of the features used by S-CAP, such as evolutionary conservation, 
iŵpliĐitlǇ iŶtegrate aŶ allele͛s iŵportaŶĐe oǀer all Đell populatioŶs aŶd tiŵe poiŶts, complementing the 
strengths of RNA-seq based methods. Another direction for the integration of S-CAP and experimental 
methods is the use of cheap and fast site-directed sequencing in a diverse array of cell types to validate 
putatively pathogenic sites identified by S-CAP47. 
Eventually, analyzing the splicing region will become commonplace in clinical settings. This is 
currently a difficult task given the complexity of splicing and the difficulty in predicting whether a 
change in splicing will result in disease. There are over five hundred rare variants of uncertain 
significance per individual in the splicing region with no clear semantic effect outside of the core splice 
sites and most are not observed in control populations. S-CAP represents a big step towards effectively 
interpreting splicing variation, but we will have to continue to improve on these methods, learning more 
from RNA-seq experiments, to render this problem more tractable. 
Online Methods 
Variant Processing 
Dataset of pathogenic and benign variants 
Pathogenic variants were obtained from two manually curated databases: the Human Gene Mutation 
Database (HGMD) Professional version 2017.1 and ClinVar release 20170406. Only HGMD variants 
tagged as Disease Mutation (DM) and ClinVar variants with Pathogenic Clinical Significance were 
included in the final set of pathogenic variants [GILL: How many variants from HGMD, how many from 
ClinVar?]. Benign variants were obtained by identifying variants observed in individuals from gnomAD34 
r2.0.2.  
Variant Annotation 
ANNOVAR48 v527 was used to annotate variants with predicted effect on protein-coding genes using 
gene isoforms from Ensembl49 gene set version 75 for the hg19/GRCh37 assembly of the human 
genome. All coding isoforms were used where the transcript start and end sites were marked as 
complete and the coding span was a multiple of three. 
Variant Filtering 
All variants were filtered so as to only include rare variants that do not directly affect the protein coding 
sequence and the splicing region [GILL: Meaning unclear. Variants outwith the obligate GT and AG 
dinucleotides or extended splice site consensus sequences? Same definition as given in Results i.e. all 
synonymous or intronic variants within 50 base-pairs18,31 of an exon boundary?]. Rare variants are 
defined to be variants with an allele frequency of ч1% in all control populations and subpopulations in 
KGP phase 3, ExAC v0.3.1 and gnomAD r2.0.2. Variants that do not affect the protein coding sequence 
are those determined to be synonymous or which in the core splicing, extended splicing or intronic 
regions. 
Positional Subsetting of Variants 
Variants at different positions relative to splice sites have different properties, such as distributions of 
sequence conservation and ratio of pathogenic variants to benign variants. This led us to allocate 
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variants into subsets based upon their position relative to splice sites and train separate models for 
each. Subsets were selected so as to group together functionally related positions. In total, we 
constructed 6 subsets (Fig. 1). We created subsets of ϯ͛ aŶd ϱ͛ core (1 or 2 bases from the splice site), 
extended (1-2 bases into the exon on the ϱ͛ side aŶd 3 to 6 bases from the ϱ͛ splice site), ϯ͛ intronic (2 to 
50 bases from the splice siteͿ, ϱ͛ iŶtroŶiĐ ;ϳ-ϱ0 ďases froŵ the ϱ͛ spliĐe siteͿ aŶd exonic (inside the exon 
but outside the extended region) regions.  
 We associated each variant with a nearby [GILL: neighboring?] exon. For variants close to 
multiple exons, we attempted to assign the variant to the exon considered as having the highest chance 
of a pathogenic effect, which we inferred from the density of pathogenic variants in each bin. 
Specifically, we favored associations in the following order: core, ϱ͛ extended, intronic, and exonic. 
Features 
Our models utilized a diverse library of previously described and novel features (fig. S1). These can be 
divided into gene level, exon level, and variant level features as well as a few features that are specific to 
individual regions. Below, we introduce our novel features and describe how we curated previously 
described features. 
Gene Level 
We obtained RVIS37 scores from, the appropriately named, genic-intolerance.org (see URLs). We used 
the data iŶ ĐoluŵŶ ͞‘VI“[pop_ŵaf_0.0ϱ%;aŶǇͿ]͟ as a feature iŶ our ŵodels. We obtained pLI34 scores 
from supplementary table 13 of the original publication on 7 April 2017. We used as a feature the 
column denoted as pLI. We obtained a haploinsufficiency score38 which is a probability of a gene being 
haploinsufficient directly from the publication page on the PLOS website in May 2017. We downloaded 
MPC, a recently proposed regional constraint score39 (see URLs). 
Exon Level 
For each exon, we created splice site features which measure the number of rare and common variants 
observed in gnomAD iŶ the ϱ͛ aŶd ϯ͛ Đore ;0-2) and extended (2-6) regions. This was motivated by the 
desire to share information between functionally similar positions. We take this feature to represent the 
ĐoŶstraiŶt oŶ the eǆoŶ͛s spliĐiŶg regioŶ iŶ the huŵaŶ populatioŶ. To avoid data leakage, when 
constructing this feature for a particular variant, we masked the effect of the variant itself on this score. 
“peĐifiĐallǇ, if a giǀeŶ ϱ͛ss had one associated core variant, it was assigned a count of 0. If it had 2, both 
were assigned a count of 1. Additionally, we measured exon identity across vertebrates and found that 
the exon identities in many organisms were highly correlated. Principal components analysis (PCA) of 
the identity scores for all exons showed that 5 components explain the vast majority of variation in the 
data. To prevent overfitting, we included the original exon identities projected onto these first 5 
principal components as features. We also included exon length and exon length mod 3 as features 
associated with each variant. 
Variant Level 
In order to consider the local sequence context of variants, we included spectrum kernel features 
representing the change in trinucleotide content induced by the variant42. For all 64 possible 
trinucleotides, we created a vector counting the number of occurrences in the alternative sequence and 
subtracted an equivalent vector for the reference sequence. The MaxEntScan reference score, 
alternative score and difference between the two were all used as features to quantify the strength of 
eaĐh eǆoŶs͛ refereŶĐe aŶd alterŶatiǀe ϱ͛ aŶd ϯ͛ splice site. SPIDEX scores27 were downloaded directly 
from the Deep Genomics website (see URLs) on 7 April 2017. Any variant not assigned a SPIDEX score 
was assigned a value of 0. We included 8 scores measuring evolutionary conservation, specifically, 
PhyloP 46way vertebrates, placental mammals, primates, PhyloP 100way vertebrates, PhastCons 
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46way vertebrates, placental mammals, primates and the PhastCons 100way vertebrates. Any base 
not annotated with a conservation score was assigned a value of 0. We also included the signed distance 
to the 5’ss and 3’ss splice site of the associated exon as features to measure base-pair importance. 
Region Specific features 
The ϯ͛ iŶtroŶiĐ “-CAP model includes a branchpoint feature modeled using LaBranchoR, a bi-directional 
LSTM (long short-term memory) model trained on the genome sequence surrounding experimentally 
validated branchpoint sites33. Specifically, we used the in silico mutagenesis scores available online (see 
URLs) as a feature. 
We explicitly represented the strength of cryptic sites created by each variant using 
MaxEntScan32. IŶ ϯ͛ iŶtroŶiĐ, ϯ͛ Đore, aŶd eǆoŶiĐ ďiŶs, ǁe iŶĐluded a ϯ͛ ĐrǇptiĐ spliĐe site ĐreatioŶ terŵ 
aŶd, iŶ the eǆoŶiĐ, ϱ͛ extended, 5͛ Đore, aŶd ϱ͛ iŶtroŶiĐ ďiŶs, ǁe iŶĐluded a ϱ͛ ĐrǇptiĐ spliĐe site ĐreatioŶ 
term. For each variant, we scanned for the highest scoring splice site motif that overlaps the variant, 
excluding reference splice sites. We used as features the strength of the cryptic site, the change in the 
strength of the cryptic site induced by the variant, the distance from the reference splice site to the 
cryptic site and the difference in strength between the cryptic site and the reference splice site. 
Model Training and Testing 
We performed 5-fold cross-validation to train and identify a generalizable S-CAP model. 5-fold cross-
validation refers to splitting the data into 5 roughly equally sized parts (folds). All variants found in a 
single gene were included in the same fold to ensure that there was no leakage of feature information 
across the training and test sets. We then merged 4 of 5 sets to form a training dataset, trained the 
model on this training dataset and evaluated on the remaining fold to obtain an expected accuracy. We 
performed this process 5 times (each combination of 4 folds was merged together to form the training 
dataset) testing on the fold that was not included in the training dataset. 
To train the S-CAP model, we used a Gradient Boosting Tree model implemented in the python 
2.7.13 sklearn version 0.18.1 library and used the default parameters to reduce the chance of overfitting 
the model. After training 5 models during the cross-validation phase, we picked the median performing 
model as the final classifier. The ROC curves were built based on performance on the test set for this 
specific median model. 
Comparison Metrics 
We sought to compare our performance to those of other methods used to infer the importance / 
pathogenicity of noncoding variants. We evaluated the performance of each of the methods below by 
using the output score directly as a pathogenicity score. For SPIDEX, we negated the score, as is 
consistent with large negative scores having a larger impact on function and constraint, respectively. We 
report performances for all subsets where the method reported scores for at least 50% of variants. 
Variants where a method did not report a score were excluded from evaluation. 
 
CADD22 v1.3 scores were downloaded from the CADD website (see URLs). SPIDEX27 scores were 
downloaded directly from the Deep Genomics website (see URLs) on 7 April 2017. Any variant not 
assigned a SPIDEX score was assigned a default value of 0. LINSIGHT24 scores were downloaded directly 
from the LINISGHT website (see URLs) on 7 April 2017. Any variants not assigned a LINSIGHT score was 
defaulted to be 0. Eigen v1.0 coding and Eigen v1.0 noncoding23 Phred scores were downloaded from 
the Eigen website (see URLs). MutPred Splice42 score were downloaded from the MutPred Splice 
website (see URLs). 
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Recessive v. Dominant Classifiers 
We developed separate classifiers for recessive and dominant acting variants iŶ the ϯ͛ aŶd ϱ͛ 
core splice site regions. We opted not to include dominant and recessive classifiers for the other 4 
regions as we did not have a sufficient number of pathogenic variants to train and evaluate multiple 
models and, in our exploration, they made less of an impact. Intuitively, for core variants the molecular 
phenotype is obvious, a loss of splicing. This places the full burden on predicting if this change will result 
in disease, a task heavily dependent upon whether the variant acts via a recessive or dominant 
mechanism. Whereas in the other regions, the majority of possible variants have little impact on 
splicing, making predictions as to whether or not the variant will have an effect on splicing is the primary 
challenge, a task unrelated to inheritance mode.  
When evaluating a patient, core variants observed as heterozygous are routed to the dominant 
classifier and variants observed to be homozygous are routed to the recessive classifier. Since there was 
no genotype information available for the labeled pathogenic and benign variants, we developed a 
framework to label variants as dominant or recessive based on their occurrence in a control population. 
We labeled pathogenic variants observed as heterozygous in the control population as likely recessive, 
because a single copy can be harbored with no major issues, and pathogenic variants never observed in 
the control population as likely dominant. Benign heterozygous variants that are never observed as 
homozygous in the healthy control population provide little information regarding their potential to 
cause a recessive acting disease. In this case, we tagged benign heterozygous variants never observed to 
be homozygous as dominant, and benign variants observed as homozygous as recessive. Additionally, as 
any variant on the X chromosome resembles a homozygous autosomal variant [GILL: I doŶ͛t folloǁ this 
reasoning. You mean in males or females?], all X chromosome variants were labelled as recessive [GILL: 
Seems reasonable]. 
 We encoded whether each variant was considered dominant or recessive as a binary feature 
and trained a single gradient boosting tree model for each region. Then, we found two 95% true positive 
rate thresholds separately based on test sets of only dominant-tagged and only recessive-tagged 
variants. 
Patient Datasets 
Sequencing and diagnosis for all patients was performed by other laboratories. All patient data were 
downloaded by requesting access to the European Genome-Phenome Archive (EGA) and the database of 
Genotype and Phenotype (dbGaP) databases. Variant call files (VCFs) for 11 patients were submitted by 
the Deciphering Developmental Disorders (DDD) study in the European Genome-Phenome Archive 
(EGA) study EGAS00001000775. An additional 3 patient VCFs were submitted to the database of 
Genotype and Phenotype (dbGaP) study phs000655.v3.p1.  
Data availability. 
S-CAP scores for all rare variants in the predefined splicing region in the human genome, along with the 
source code, and final trained model for the S-CAP classifier, are available through the S-CAP website 
(see URLs), licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. 
The S-CAP code repository is also available at Bitbucket (see URLs). 
URLs 
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S-CAP website, http://bejerano.stanford.edu/mcap; S-CAP codebase [GILL: This URL does not connect 
with anything as yet], https://bitbucket.org/bejerano/splicing_classifier ;RVIS, http://genic-
intolerance.org/data/RVIS_Unpublished_ExACv2_March2017.txt; SPIDEX, 
https://www.deepgenomics.com/spidex-noncommercial-download [GILL: This U‘L doesŶ͛t ǁork]; 
LINSIGHT, http://compgen.cshl.edu/~yihuang/LINSIGHT/; Haploinsufficiency, 
https://doi.org/10.1371/journal.pgen.1001154 [GILL: This URL is for a manuscript, Huang et al. (2010) 
which is given as no. 38 in your list of references] ; LabranchOR, 
http://bejerano.stanford.edu/labranchor/; ExAC, 
ftp.broadinstitute.org/pub/ExAC_release/release1/regional_missense_constraint/ 
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Figures and Tables 
Table 1 
 Method 
Region CADD LINSIGHT,EIGEN,SPIDEX MutPred Splice 
 Author͛s Thresholds 
ш20 N/A ш0.6 
ϯ͛ 
intronic 
99% N/A N/A 
ϯ͛ Đore 4% N/A N/A 
exonic 98% N/A 48% 
ϱ͛Đore 2% N/A N/A 
ϱ͛ 
extended 
96% N/A N/A 
ϱ͛ 
intronic 
97% N/A N/A 
Total 31% N/A 48% 
Table 1. Misclassification rate of existing metrics at author-provided thresholds. Averaging 
across all regions, the CADD and MutPred Splice author-recommended thresholds result in the 
misclassification of 31% and 48% of pathogenic variants, respectively. It should be noted that 
MutPred Splice can only be applied to synonymous variants in exonic regions. Other existing 
tools, like LINSIGHT, EIGEN and SPIDEX, do not provide a default threshold, rendering them 
difficult to use for classification purposes. 
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Table 2 
region CADD LINSIGHT EIGEN SPIDEX MutPred 
Splice 
S-CAP 
ϯ͛ iŶtroŶiĐ ш 0.709 ш 0.048 ш 3.57 ч -1.45 N/A ш 0.005 
ϯ͛ Đore  ш 21.50 ш 0.767 ш 7.25 ч  1.14 N/A Dom.: ш 0.031 
Rec.: ш 0.144 
Exonic ш 0.061 ш 0.086 ш 3.78 ч  -2.31 ш 0.090 ш 0.012 
ϱ͛ Đore ш 22.6 ш 0.795 ш 8.381 ч  1.65 N/A Dom.: ш 0.032 
Rec.:  ш 0.357 
ϱ͛ eǆteŶded ш 7.423 ш 0.211 ш 13.80 ч  -0.910 N/A ш 0.003 
ϱ͛ iŶtroŶiĐ ш 0.852 ш 0.047 ш 0.847 ч  -1.636 N/A ш 0.004 
 
Table 2.  High sensitivity thresholds after recalibrating each method. We retuned each existing 
method for each of the six regions by finding the smallest threshold that resulted in the correct 
classification of 95% of pathogenic variants from that region. S-CAP thresholds for all regions 
(including the dominant and recessive modes) are included in the last column. By definition, 
with the high sensitivity thresholds each method will misclassify at most 5% of known 
pathogenic mutations, but their effectiveness at correctly classifying benign variants and 
reducing the number of patient VUS will vary greatly. 
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 Table 3 
Table 3. Causative variants in each patient and pathogenicity predictions. Each row describes 
a single patient, their underlying disease, causative variant and its zygosity, the region of the 
associated gene in which it is located, and the score and percentile each method assigns to the 
variant. The percentile was computed by measuring the fraction of variants in the same region 
with a score less than the score assigned to the causative variant. The 99th percentile denotes 
that 99% of variants in that region have a score less pathogenic than the one we are observing 
thereby indicating that the variant is considered to be highly pathogenic. Dark and light green 
filled entries have the highest and second highest percentile scores for the given variant, 
Patient_ID Disease 
chr:pos 
(hg19) 
Zygosity Region SCAP (%-ile) 
SPIDEX (%-
ile) 
CADD (%-ile) 
LINSIGHT (%-
ile) 
EIGEN (%-ile) 
DDDP102313 
Koolen-de-
vries 
syndrome 
17:44144914 
C>T 
Heterozygous 5' Core 0.081 (63.3) -14.532(52.6) 25.8 (77.5) 0.978 (65.6) 15.932 (49.0) 
DDDP100243 
Claes-Jensen 
type mental 
retardation 
X:53245380 
C>A 
Hemizygous 3' Core 0.919 (99.1) -1.305 (22.1) 24.8 (65.02) 0.822 (23.2) N/A 
DDDP110794 
Mental 
Retardation 
3:71037144 
C>T 
Heterozygous 5' Core 0.217 (88.2) -23.241(69.6) 26.4 (86.9) 0.988 (90.8) 20.234 (73.9) 
DDDP111322 
Nephrotic 
Syndrome 
19:36333453 
C>T 
Compound 
Heterozygous 
3' Core 0.629 (38.5) -1.67 (24.2) 25 (69.8) 0.97 (54.8) 14.702 (40.2) 
DDDP102111 
Epileptic 
encephalopat
hy 
2:166165305 
G>A 
Heterozygous 5' Core 0.348 (93.6) -32.609 (82.8) 25 (59.8) 0.988 (90.8) 26.022 (87.7) 
DDDP108825 
Cohen 
Syndrome 
8:100729602 
G>A 
Compound 
Heterozygous 
5' Core 0.879 (94.2) -7.189 (35.5) 25.1 (62.2) 0.982 (79.2) 25.405 (85.5) 
DDDP100128 
Sotos 
Syndrome 
5:176673677 
A>G 
Heterozygous 3' Core 0.137 (81.4) -12.574 (61.1) 22.9 (24.8) 0.961 (94.5) 9.876 (18.6) 
DDDP111152 
Ehlers-Danlos 
Syndrome 
2:189873948 
G>A 
Heterozygous 5' Core 0.777 (98.6) -5.594 (31.1) 27.9 (97.5) 0.989 (92.9) 29.666 (90.5) 
DDDP102594 
Mental 
Retardation 
X:135095506 
A>G 
Hemizygous 3' Core 0.758 (98.6) -2.955 (31.0) 24.3 (52.9) 0.874 (29.6) N/A 
DDDP111486 
Noonan 
Syndrome 
11:11914887
4 A>T 
Heterozygous 3' Core 0.539 (97.6) -28.352 (89.7) 24.9 (67.4) 0.982 (79.3) 22.809 (80.2) 
DDDP100281 
Epileptic 
encephalopat
hy 
16:56370773 
G>A 
Heterozygous 5' Core 0.151 (82.1) -7.739 (37.0) 26.6 (89.2) 0.987 (88.5) 24.055 (84.9) 
C11 
Congenital 
fiber-type 
disproportion 
19:38958362 
C>T 
Heterozygous Exonic 0.657 (97.8) -0.366 (89.6) 19.430 (97.6) N/A 7.879 (19.8) 
C1 
Dystroglycan
opathy 
1:46655129 
C>A 
Compound 
Heterozygous 
5' Core 0.817 (77.03)  -52.028 (95.9) 21.500 (14.3) 0.992 (96.8) 4.976 (7.63)  
1:46660532 
G>A 
Exonic 0.095 (83.0) -1.556 (96.4) 12.050 (79.2) N/A 21.658 (76.5) 
E2 
Nemaline 
myopathy 
2:152520057 
C>T Compound 
Heterozygous 
5' Extended 0.147 (98.9)  -11.190 (85.4) 19.680 (97.9) 0.981 (79.2) 20.272 (65.0) 
2:152544805 
C>T 
5' Core 0.915 (99.1) -2.970 (22.6) 27.200 (94.1) 0.990 (94.7) 20.384 (74.5) 
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respectively. Red entries highlight patients where the causative variant would have been 
classified as benign using the author-recommended thresholds.
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Figure 1 
 
Figure 1. Distribution of rare, noncoding variants in the splicing region. We built two sets of rare 
variants near exons that have no effect on the annotated coding sequence: (A) a set of likely benign 
variants from the Genome Aggregation Database (gnomAD) and (B) a set of putatively pathogenic 
variants from the Human Gene Mutation Database (HGMD) and ClinVar. We developed a simple model 
to ascertain the effect of these variants on splicing, using MaxEntScan to assess if a variant created a 
cryptic splice site or disrupted the reference splice site, and LaBranchoR in silico mutagenesis scores to 
assess if a variant disrupted a branchpoint. In (A) and (B), we plot the aggregate counts of each variant 
set as a function of position relative to the nearest splice site, colored by their putative effect. Nearly 
97% of pathogenic variants in the splicing region [GILL: ǁhat do Ǉou ŵeaŶ ďǇ the ͚spliĐiŶg regioŶ͛?] are 
predicted to have an effect [GILL: Do you mean a deleterious effect or any effect?] on splicing, as 
compared to only 18% of benign variants. (C) We split the variants into different regions with largely 
homogenous function. The majority of known pathogenic variants are found in the ϯ͛ aŶd ϱ͛ Đore spliĐe 
site regions, whereas the ŵajoritǇ of ďeŶigŶ ǀariaŶts are fouŶd iŶ the ϯ͛ iŶtroŶiĐ, eǆoŶiĐ aŶd ϱ͛ iŶtroŶiĐ 
Region 3’	Intronic 3’	Core Exonic 5’	Core 5’ Extended 5’	Intronic
HGMD +	ClinVar 1308 4500 290 6309 2272 159
gnomAD 2357091 42880 1899048 58942 210618 2191871
KGP	median 169 2 167 3 16 176
ag GUaaguynyuray yyyncAG
4448 exon 3+4
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regions. In a typical individual, the distribution of variants is similar to the distribution of gnomAD benign 
variants.   
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Figure 2 
 
Figure 2. Overall performance per region for splicing pathogenicity classification. For each method, 
1000 threshold points were determined by evenly spanning the range from the minimum to the 
maximum score observed for the method. A true positive rate and false positive rate were determined 
for each threshold value and used to build the receiver operating characteristic (ROC) curve. S-CAP 
achieves an AUC of 0.953 iŶ the ϯ͛ iŶtroŶiĐ regioŶ ;AͿ, aŶ AUC of 0.ϴ0ϰ iŶ the ϯ͛ Đore sites ;B), an AUC of 
0.826 in the exonic region (C), an AUC of 0.805 iŶ the ϱ͛ Đore sites ;DͿ, aŶ AUC of 0.ϴϵ2 iŶ the ϱ͛ 
eǆteŶded regioŶ ;EͿ aŶd aŶ AUC of 0.ϴϱϮ iŶ the ϱ͛ iŶtroŶiĐ regioŶ ;FͿ. “-CAP outperforms existing metrics 
in all regions and no existing method consistently outperforms the rest [GILL:…..ǁhereas none of the 
existing method consistently outperformed the others?].  
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Figure 3. 
 
Figure 3. Overall performance on patient data. Since we have defined separate models for 6 different 
regions and separate the 2 core regions into dominant and recessive, there are 8 different AUC curves 
for each method. We take a weighted sum of each AUC based on the distribution of variants seen in a 
typical individual to form an overall receiver operating characteristic (ROC) curve representative of the 
overall performance expected on patients. (A) S-CAP achieves an AUC of 0.876 and (B) an hsr-AUC of 
0.288. (C) S-CAP reduces the number of splicing related variants of uncertain significance (VUS) from 
patient exomes by 40% while maintaining the pathogenic variants with 95% sensitivity. At the same 
sensitivity requirement, existing methods reduce the VUS by at most 15%. (D) We observe a similar 
reduction in VUS overall (n=2054) Thousand Genomes Project individuals, which conceptually only differ 
from Mendelian disease patients by up to 2 mutations. 
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Supplementary Figures 
Supplementary Table 1 
Feature Category Features Description 
Chromosome Level  X, Y or not XY 3 binary features to indicate whether a variant is found on 
the autosomes or the X or Y chromosome 
Gene Level  RVIS Measure of gene mutability. Observed v. Expected variant 
abundance 
pLI Measure of gene loss of function tolerance.  
haploinsufficiency score Recessive or dominant gene inheritance 
Exon Level  # rare 3’ core variants rare variants observed in 3’ core region 
# rare 5’ core variants rare variants observed in 5’ core region 
# common 3’ core variants common variants observed in 3’ core region 
# common 5’ core variants common variants observed in 5’ core region 
# rare 3’ extended variants rare variants observed in 3’ extended region 
# rare 5’ extended variants rare variants observed in 5’ extended region 
# common 3’ extended variants common variants observed in 3’ extended region 
# common 5’ extended variants common variants observed in 5’ extended region 
exon % identity Measure the % identity of hg19 exon with each of the 99 
species in the multiz100way. Take top 6 PCA components 
after fitting a PCA to all coding exons.  
exon length Number of bases in the exon 
exon length % 3 Number of bases modulo 3 
MPC Regional mutational constraint score 
Variant Level  Spectrum Kernel Count of all 3-mers introduced and removed by mutation 
MaxEntScan The difference in motif match 
SPIDEX Predicted �� (change in exon expression) 
distance to 5’ SS Number of bases to the 5’ splice site 
distance to 3’ SS Number of bases to the 3’ splice site 
CADD Functional data SVM-based classifier 
LINSIGHT Conservation based model to identify variants under 
negative selection. 
PhyloP Base-pair conservation across primates, mammals and 
vertebrates 
PhastCons Regional conservation across primates, mammals and 
vertebrates 
3’ Intronic  LaBranchoR Sequence based deep learning branchpoint prediction 
3’ Intronic, 3’ Core, 
Exonic  
3’ cryptic splice site creation terms MaxEntScan based feature to measure cryptic splice 
creation near the 3’ side 
Exonic, 5’ Core, 5’ 
Extended, 5’ Intronic  
5’ cryptic splice site creation terms MaxEntScan based feature to measure cryptic splice 
creation near the 5’ side 
3’ Core, 5’ Core Zygosity Indicates whether the variant is seen in a heterozygous or 
homozygous state. 
 
Supplementary Table 1. Description of features used to build S-CAP. The chromosome, 
gene, exon and variant level features were used in all models for all regions. There was an 
additional set of features that was specific to certain regions. These are enumerated in the table 
below the variant level features section.   
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Supplementary Figure 1 
 
 
Supplementary Figure 1. Framework for training and evaluating 6 pathogenicity models. The splicing 
region is split into 6 independent regions as defined in Fig. 1c. and a separate model is trained for 
variants residing in each region. For the ϱ͛ aŶd ϯ͛ Đore regioŶs, ǁe additioŶallǇ defiŶed separate 
dominant and recessive classifiers (not shown) leading to a total of 8 models. Given a set of variants to 
be scored, we calculate the S-CAP score for each variant by using the corresponding model associated 
with the region where the variant is found.   
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Supplementary Figure 2. 
A                                                                           B 
 
Supplementary Figure 2. Performance of S-CAP compared to MutPred Splice. MutPred 
Splice is a computational method for predicting the pathogenicity of exonic synonymous 
variants. MutPred Splice was trained by its authors using a subset of the pathogenic data used to 
train/test S-CAP. As a result, we need to independently test MutPred Splice on a set of variants 
that was not used in its training. This test set comprises rare synonymous variants from HGMD 
added to the database in 2013 or later. On this set, S-CAP achieves an AUC of 0.838 while 
MutPred Splice achieves an AUC of 0.793. S-CAP performs especially well in the high 
sensitivity domain with a hsr-AUC of 0.246 as compared to 0.081 for MutPred Splice. 
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Supplementary Figure 3. 
 
Supplementary Figure 3. S-CAP performance in the high sensitivity region. The hsr-AUC curve is formed 
by subsetting the overall AUC to just the region where pathogenic variants are correctly classified over 
95% of the time. An hsr-AUC curve is calculated for each of the regions as defined in Fig. 1C.  S-CAP 
achieves an hsr-AUC of 0.549 iŶ the ϯ͛ iŶtroŶiĐ regioŶ ;AͿ, aŶ hsr-AUC of 0.257 iŶ the ϯ͛ Đore sites ;BͿ, aŶ 
hsr-AUC of 0.186 in the exonic region (C), 0.291 iŶ the ϱ͛ Đore sites ;DͿ, 0.ϰ29 in the ϱ͛ eǆteŶded regioŶ 
(E) and 0.322 iŶ the ϱ͛ iŶtroŶiĐ regioŶ ;FͿ. “-CAP outperforms existing metrics in all regions in the high 
sensitivity domain whereas none of the existing methods consistently outperforms the others [GILL: Is 
this what you want to say?]. 
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Supplementary Figure 4 
 
Supplementary Figure 4. Performance on recessive and dominant classes. The distribution of the 
underlying features is dramatically different for dominant and recessive variants. This results in a big 
difference in performance when classifying recessive and benign variants in the core splice site regions. 
S-CAP achieves an AUC (A) of 0.779 on dominant tagged variants and (B) of 0.880 on recessive tagged 
ǀariaŶts iŶ the ϱ͛ Đore regioŶ. There is a siŵilar perforŵaŶĐe differeŶĐe iŶ the ϯ͛ Đore regioŶ ǁhere “-
CAP achieves an AUC (C) of 0.805 on dominant tagged variants (D) and of 0.890 on recessive tagged 
variants. In the high sensitivity region, S-CAP achieves an hsr-AUC (E, F) of 0.222 on dominant tagged 
variants and of 0.518 oŶ reĐessiǀe tagged ǀariaŶts iŶ the ϱ͛ Đore regioŶ ;G, H) and of 0.296 on dominant 
tagged variants and of 0.454 of reĐessiǀe tagged ǀariaŶts iŶ the ϯ͛ Đore regioŶ. 
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